We believe the cannabis industry as a whole has a responsibility to help our legislators in every way possible to arrive an encompassing evidenced based approach, maintaining public safety to achieve the Ontario Government’s ambitions for both medical and responsible well- educated adult use markets
Toronto, ON (PRWEB) September 15, 2017
International Cannabis Solutions, based out of Toronto, Ontario, Canada; has a global reach with an expert team with over 150 years of cumulative experience in healthcare, education, pain management, addiction medicine, pharmacology, and more specifically, Cannabis and Cannabinoid knowledge. We are uniquely positioned to address the Federal Government’s Cannabis Task Force recommendations and needs analysis findings to provide evidenced based knowledge and consultancy for all levels of government within Canada and globally.
Following the Ontario provincial government’s announcement of a framework for legal cannabis sales and use, International Cannabis Solutions Incorporated would like to offer the following statements:
We applaud the Ontario governments recognition of the time sensitive nature of this initiative and their commitment to meet the Canadian Federal Governments time line for legalization of Cannabis in Canada July, 1st, 2018
Keeping the age at which an individual can legally obtain cannabis at 19 (i.e. in line with alcohol purchase) is a prudent move. First, it reduces the risk of co-ingestion also it creates a preventive framework for youth. Protecting the developing brains of our next generation (our youth) is imperative.
We are encouraged by the Ontario government’s commitment to education, as it is necessary not only to mitigate risk, but also to educate the general public on the features, benefits and responsible use associated with cannabis to make informed decisions. Educational programming should ‘evidenced based’ where possible at all times.
We encourage a further look to successful international development in the industry as part of “The Ontario Government” ongoing process, ie. Portugal, The Netherlands.
“We believe the cannabis industry as a whole has a responsibility to help our legislators in every way possible to arrive an encompassing evidenced based approach, maintaining public safety to achieve the Ontario Government’s ambitions for both medical and responsible well- educated adult use markets. We are encouraged that there will be further stakeholder consultations before the final bill is tabled in the fall of 2017 and ICS would be willing participants in these consultations. We look forward to hearing further details regarding the development of distribution channels and we are excited to contribute in any way we can to provide all levels of government our expertise,”. said Kevin Hall, President and CEO of International Cannabis Solutions.
Dr. Peter M Blecher, (Medical Director, CPM Centre for Pain Management, Oshawa; Global VP & Medical Director, ICS; Chief Medical Officer, Starseed Medicinal, Inc) had this to say : “As both an ER doctor and chronic pain physician who has been practicing in the province of Ontario for well over 20 years, I have been first-hand witness to the ravages and devastation that opioids have had in our society. The growing adoption and judicious use of opioid-sparing cannabinoids, has frankly transformed my pain practice, and that of many of my colleagues. While no one thing will ever be a ‘panacea’ for eliminating suffering, the use of cannabinoids is having in immense positive impact on thousands of patients, in more safely managing their pain symptoms, and co-morbidities of anxiety and poor sleep hygiene, to mention just a few.
I am delighted to be associated with ICS, in helping them to further my own commitment to bring evidence-based education about medical cannabis to not only my colleagues and patients, but to the broader stakeholders such as trade unions, insurers, and government agencies – all of whom should have strong vested interests in this seeing this exciting frontier of medicine being managed properly and ethically, while remaining sympathetic to the countless patients relying on this plant’s still-emerging and extraordinary medical potential.”
Furthermore, ICS Canada has collaborative enterprises with a variety of important stakeholders, from which consultation and resources are shared in order to move the field forward. With Ontario Government pro-action as indicated by their announcements today, particular stakeholder groups such as Licenced Producers will also be impacted by these decisions.
“We are delighted to have clarity on the intended distribution model for the province of Ontario. We can now align the distribution aspects of our business more specifically to this plan and project the costs associated with product delivery with more certainty. We are excited to start doing business in Ontario. Furthermore, we are encouraged by the decision to engage with industry stakeholders with a focus on health and safety. For IFP, achieving the highest possible standards for cannabis production is a primary guiding objective.,” added Paul Grenier, Lead Business Strategist – Intrinsic Farmed Products – Late Stage ACMPR Applicant
Kevin Hall and other ICS stakeholders are available to media for interviews.
Share article on social media or email: